ADMA Biologics, Inc. (ADMA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Is ADMA Biologics, Inc. stock overvalued or undervalued in 2026?
ADMA Biologics, Inc. (ADMA) trades at 15.8× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: ADMA Biologics, Inc.
Market cap $2B · 52 weeks $8 – $20 (46 % below the high) · P/E 15.8× · 2027 est. P/E 11.7× · Dividend none · Next earnings November 4, 2026 · expected EPS $0.20 · Closing price, Nov 2 · accounts published Aug 5.
- Valuation: P/Sales 6.5× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.2 %, fails.
- Market cap / Cash 30.1×, fails.
- Annual cash burn $0.21, passes.
- Total Debt 1.0×, passes.
Against its peers (reference peers) — ADMA Biologics, Inc.: P/E 15.8×; EV/EBITDA 10.9×; ROIC 27.6 %; $2.5B. Grifols, S.A. (P/E 16.4×; EV/EBITDA 8.3×; ROIC 5.5 %; $7.2B), Harmony Biosciences Holdings, Inc. (P/E 12.3×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.2B), Nurix Therapeutics, Inc. (P/E 11.1×; EV/EBITDA 6.7×; ROIC 25.9 %; $2.8B).
Profitability
| Return on Equity | 39.59% |
| Return on Invested Capital | 27.55% |
| Return on Assets | 24.69% |
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Net Margin | 32.98% |
Financial Health
| Debt / Equity | 0.50 |
| Current Ratio | 6.97 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 19.98 |
Price Performance
| 1 month | +13.79% |
| 3 months | +19.44% |
| Year-to-date | -39.36% |
| 1 year | -28.04% |
| 3 years | +203.01% |
| 5 years | +684.40% |
| 10 years | +120.76% |
Related companies: GRFS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of ADMA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks